ACRS Stock Summary and Trading Ideas (Aclaris Therapeutics | NASDAQ:ACRS)

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Aclaris Therapeutics trades on the NASDAQ stock market under the symbol ACRS.

As of February 6, 2026, ACRS stock price climbed to $3.57 with 1,495,825 million shares trading.

ACRS has a beta of 1.16, meaning it tends to be more sensitive to market movements. ACRS has a correlation of 0.05 to the broad based SPY ETF.

ACRS has a market cap of $386.56 million. This is considered a Small Cap stock.

Last quarter Aclaris Therapeutics reported $3 million in Revenue and -$.12 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.02.

In the last 3 years, ACRS traded as high as $14.53 and as low as $.59.

The top ETF exchange traded funds that ACRS belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

ACRS has outperformed the market in the last year with a return of +46.9%, while the SPY ETF gained +15.1%. In the last 3 month period, ACRS beat the market returning +57.3%, while SPY returned +3.3%. However, in the most recent 2 weeks ACRS has underperformed the stock market by returning -20.7%, while SPY returned +0.2%.

ACRS support price is $3.18 and resistance is $3.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRS shares will trade within this expected range on the day.